In 2019, Amgen and Mirati Therapeutics announced covalent irreversible inhibitors as a treatment for cancer that targeted one form (G12C) [126] of mutated KRAS (AMG 510 and MRTX 849) [126]. Here, KRAS is linked to cancer.